Pharmacodynamic trial of nimotuzumab in unresectable squamous cell carcinoma of the head and neck: A SENDO Foundation study

Clinical Cancer Research

Volumn 16, Issue 8, 2010, Pages 2474-2482

  Rojo, Federico ^a,d   Gracias, Elías ^e   Villena, Nadia ^a   Cruz, Teresa ^e   Corominas, Josep Maria ^a,b   Corradino, Irene ^g   Cedeño, Mercedes ^f   Campas, Clara ^a   Osorio, Marta ^e   Iznaga, Normando ^h   Bellosillo, Beatriz ^a,b   Rovira, Ana ^a   Marsoni, Silvia ^g   Gascon, Pere ^c   Serrano, Sergio ^a,b   Sessa, Cristiana ^h   Crombet, Tania ^f   Albanell, Joan ^a,b  

^a HOSPITAL DEL MAR   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

^d Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^e INSTITUTO NACIONAL DE ONCOLOGÍA Y RADIOBIOLOGÍA   (Cuba)

^f CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

^g SENDO Foundation   (Italy)

^h REGIONAL HOSPITAL OF LUGANO   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; KI 67 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NIMOTUZUMAB; PROTEIN KINASE B;

ADULT; ADVERSE OUTCOME; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER TISSUE; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG TOLERABILITY; FEMALE; FEVER; HEAD AND NECK CARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PHASE 1 CLINICAL TRIAL; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RADIATION DOSE; RASH; SKIN; SKIN TUMOR; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE; TUMOR BIOPSY; UPREGULATION;

AGED; ANTIBODIES, MONOCLONAL; CARCINOMA, SQUAMOUS CELL; COHORT STUDIES; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, EPIDERMAL GROWTH FACTOR; SKIN; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 77950963650     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-3042     Document Type: Article

References (42)

1. Mateo C, Moreno E, Amour K, Lombardero J, Harris W, Perez R. Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity. Immunotechnology 1997;3:71-81. (Pubitemid 27197395)
2. Fernandez A, Spitzer E, Perez R, et al. A new monoclonal antibody for detection of EGF-receptors in Western blots and paraffin-embedded tissue sections. J Cell Biochem 1992;49:157-165
3. Talavera A, Friemann R, Gomez-Puerta S, et al. Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation. Cancer Res 2009;69:5851-5859
4. Crombet T, Torres L, Neninger E, et al. Pharmacological evaluation of humanized anti-epidermal growth factor receptor, monoclonal antibody h-R3, in patients with advanced epithelial-derived cancer. J Immunother 2003;26:139-148 (Pubitemid 36292784)
5. Allan DG. Nimotuzumab: evidence of clinical benefit without rash. Oncologist 2005;10:760-761
6. Boland WK, Bebb G. Nimotuzumab: a novel anti-EGFR monoclonal antibody that retains anti-EGFR activity while minimizing skin toxicity. Expert Opin Biol Ther 2009;9:1199-1206
7. Akashi Y, Okamoto I, Iwasa T, et al. Enhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status. Br J Cancer 2008;98:749-755 (Pubitemid 351272610)
8. Crombet T, Osorio M, Cruz T, et al. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol 2004;22:1646-1654 (Pubitemid 41079803)
9. Crombet T, Figueredo R, Catala M, et al. Use of the humanized anti-EGFR antibody nimotuzumab and radiation for the treatment of patients with high-grade astrocytic tumors. ASCO Annual Meeting Proceedings. J Clin Oncol 2005;23:117s.
10. Rivera F, Vega-Villegas ME, Lopez-Brea MF, Marquez R. Current situation of panitumumab, matuzumab, nimotuzumab and zalutumumab. Acta Oncol 2008;47:9-19.
11. Astsaturov I, Cohen RB, Harari P. EGFR-targeting monoclonal antibodies in head and neck cancer. Curr Cancer Drug Targets 2007;7:650-665
12. Loeffler-Ragg J, Schwentner I, Sprinzl GM, Zwierzina H. EGFR inhibition as a therapy for head and neck squamous cell carcinoma. Expert Opin Investig Drugs 2008;17:1517-1531
13. Lenz HJ. Anti-EGFR mechanism of action: antitumor effect and underlying cause of adverse events. Oncology (Williston Park) 2006;20:5-13.
14. LoRusso P. Toward evidence-based management of the dermatologic effects of EGFR inhibitors. Oncology (Williston Park) 2009;23: 186-194
15. Booth CM, Calvert AH, Giaccone G, Lobbezoo MW, Seymour LK, Eisenhauer EA. Endpoints and other considerations in phase I studies of targeted anticancer therapy: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT). Eur J Cancer 2008;44:19-24. (Pubitemid 350256933)
16. Shin DM, Donato NJ, Perez-Soler R, et al. Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin Cancer Res 2001;7:1204-1213
17. Malik SN, Siu LL, Rowinsky EK, et al. Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients. Clin Cancer Res 2003;9:2478-2486 (Pubitemid 36842087)
18. Albanell J, Rojo F, Averbuch S, et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 2002;20:110-124
19. Rojo F, Tabernero J, Albanell J, et al. Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma. J Clin Oncol 2006;24:4309-4316 (Pubitemid 46630789)
20. Moral M, Paramio JM. Akt pathway as a target for therapeutic intervention in HNSCC. Histol Histopathol 2008;23:1269-1278
21. Tan AR, Yang X, Hewitt SM, et al. Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor. J Clin Oncol 2004;22:3080-3090
22. Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 2006;6:803-812
23. Baselga J, Albanell J, Ruiz A, et al. Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. J Clin Oncol 2005;23:5323-5333 (Pubitemid 46206986)
24. Li B, Chang CM, Yuan M, McKenna WG, Shu HK. Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas. Cancer Res 2003;63:7443-7450
25. Ono M, Hirata A, Kometani T, et al. Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation. Mol Cancer Ther 2004;3:465-472 (Pubitemid 39193724)
26. Crombet-Ramos T, Rak J, Perez R, Viloria-Petit A. Antiproliferative, antiangiogenic and proapoptotic activity of h-R3: a humanized anti-EGFR antibody. Int J Cancer 2002;101:567-575
27. Robert C, Soria JC, Spatz A, et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 2005;6:491-500.
28. Perez-Soler R, Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J Clin Oncol 2005; 23:5235-5246
29. Saif MW, Kim R. Incidence and management of cutaneous toxicities associated with cetuximab. Expert Opin Drug Saf 2007;6:175-182 (Pubitemid 46380811)
30. Li T, Perez-Soler R. Skin toxicities associated with epidermal growth factor receptor inhibitors. Target Oncol 2009;4:107-119
31. Mascia F, Mariani V, Girolomoni G, Pastore S. Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation. Am J Pathol 2003; 163:303-312
32. Mimeault M, Bonenfant D, Batra SK. New advances on the functions of epidermal growth factor receptor and ceramides in skin cell differentiation, disorders and cancers. Skin Pharmacol Physiol 2004;17:153-166
33. Tabernero J, Cervantes A, Rivera F, et al. Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study. J Clin Oncol 2010;28:1181-1189
34. Dawson JP, Bu Z, Lemmon MA. Ligand-induced structural transitions in ErbB receptor extracellular domains. Structure 2007;15: 942-954 (Pubitemid 47212750)
35. Ferguson KM. Active and inactive conformations of the epidermal growth factor receptor. Biochem Soc Trans 2004;32:742-745 (Pubitemid 39524368)
36. Kang ES, Oh MA, Lee SA, et al. EGFR phosphorylation-dependent formation of cell-cell contacts by Ras/Erks cascade inhibition. Biochim Biophys Acta 2007;1773:833-843
37. Keese M, Magdeburg RJ, Herzog T, et al. Imaging epidermal growth factor receptor phosphorylation in human colorectal cancer cells and human tissues. J Biol Chem 2005;280:27826-27831 (Pubitemid 41076898)
38. Diaz Miqueli A, Blanco R, Garcia B, et al. Biological activity in vitro of anti-epidermal growth factor receptor monoclonal antibodies with different affinities. Hybridoma (Larchmt) 2007;26:423-431
39. Viloria-Petit A, Crombet T, Jothy S, et al. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res 2001;61:5090-5101 (Pubitemid 32681540)
40. Garrido G, Rabasa A, Gracia E, et al. Binding properties of the anti-EGFR monoclonal antibody, nimotuzumab, limit interaction with the EGFR in renal and epidermal cells. Proc AACR, 100th Annual Meeting. Philadelphia (PA): AACR 2009; 50:abstr 2763.
41. Winquist E, Nabid A, Sicheri A, et al. A phase I dose escalation study of a humanized monoclonal antibody to EGFR (hR3) in patients with locally advanced squamous cell cancer of the head and neck (SCCHN) treated with radiotherapy (RT). Proc Am Soc Clin Oncol 2002;21:abstr 926.
42. Reddy BK, Vidyasagar MS, Koteshwar R, et al. A phase IIb 4-arm open-label randomized study to assess the safety and efficacy of h-R3 monoclonal antibody against EGFR in combination with chemoradiation therapy or radiation therapy in patients with advanced (stage III or IVA) inoperable head and neck cancer. J Clin Oncol 2009;27:abstr 6041.